tadalafil has been researched along with Cardiac Hypertrophy in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Deng, X; Li, W; Peng, Y; Wang, Y; Xiao, Y; Xiao, Z; Zeng, Y | 1 |
| Chau, VQ; Hoke, NN; Kukreja, RC; Salloum, FN | 1 |
| Burgoyne, JR; Eaton, P; Grover, S; Kass, D; Prysyazhna, O; Scotcher, J | 1 |
3 other study(ies) available for tadalafil and Cardiac Hypertrophy
| Article | Year |
|---|---|
Ligation of patent ductus venosus in a child with pulmonary arterial hypertension and hypersplenism: A case report.
Topics: Aftercare; Antihypertensive Agents; Bosentan; Cardiomegaly; Child, Preschool; Combined Modality Therapy; Echocardiography; Humans; Hypersplenism; Ligation; Male; Portal Vein; Pulmonary Arterial Hypertension; Radiography, Thoracic; Tadalafil; Tomography, X-Ray Computed; Treatment Outcome; Vascular Malformations; Vascular Resistance; Vasodilator Agents | 2020 |
Tadalafil prevents acute heart failure with reduced ejection fraction in mice.
Topics: Animals; Apoptosis; Carbolines; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Heart Failure; Male; Mice; Mice, Inbred ICR; Myocardial Infarction; Phosphodiesterase Inhibitors; Pulmonary Edema; Tadalafil; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation.
Topics: Animals; Cardiomegaly; Cyclic GMP; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic Nucleotide Phosphodiesterases, Type 5; Disulfides; Doxorubicin; Heart Failure; Mice; Mice, Mutant Strains; Oxidation-Reduction; Phosphodiesterase 5 Inhibitors; rho-Associated Kinases; Second Messenger Systems; Tadalafil | 2016 |